TrialNature communications2025

DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B.

Keun-Wook Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.